ASTX727, an oral combination of decitabine with the CDA inhibitor cedazuridine, has recently been FDA approved for MDS [180] and is currently being tested in a phase III trial compared to decitabine in MDS and low-blast-count AML (NCT03306264). This evidence concerns the gene CDA and acute myeloid leukemia.